An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections

Abstract Scarcity of effective treatments against sepsis is daunting, especially under the contemporary standpoints on antibiotics resistance, entailing the development of alternative treatment strategies. Here, we describe the design and antibiotic adjuvant properties of a new lipopeptide-like pent...

Full description

Bibliographic Details
Main Authors: Ohad Meir, Fadia Zaknoon, Amram Mor
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-21526-4
_version_ 1811336475667595264
author Ohad Meir
Fadia Zaknoon
Amram Mor
author_facet Ohad Meir
Fadia Zaknoon
Amram Mor
author_sort Ohad Meir
collection DOAJ
description Abstract Scarcity of effective treatments against sepsis is daunting, especially under the contemporary standpoints on antibiotics resistance, entailing the development of alternative treatment strategies. Here, we describe the design and antibiotic adjuvant properties of a new lipopeptide-like pentamer, decanoyl-bis.diaminobutyrate-aminododecanoyl-diaminobutyrate-amide (C10BBc12B), whose sub-maximal tolerated doses combinations with inefficient antibiotics demonstrated systemic efficacies in murine models of peritonitis-sepsis and urinary-tract infections. Attempts to shed light into the mechanism of action using membrane-active fluorescent probes, suggest outer-membrane interactions to dominate the pentamer’s adjuvant properties, which were not associated with typical inner-membrane damages or with delayed bacterial growth. Yet, checkerboard titrations with low micromolar concentrations of C10BBc12B exhibited unprecedented capacities in potentiation of hydrophobic antibiotics towards Gram-negative ESKAPE pathogens, with an apparent low propensity for prompting resistance to the antibiotics. Assessment of the pentamer’s potentiating activities upon efflux inhibition incites submission of a hitherto unreported, probable action mechanism implicating the pentamer’s de-facto capacity to hijack bacterial efflux pumps for boosting its adjuvant activity through repetitive steps including outer-membrane adhesion, translocation and subsequent expulsion.
first_indexed 2024-04-13T17:40:05Z
format Article
id doaj.art-cfa701f62a5d46c6ad64b004ce8f4dd3
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-13T17:40:05Z
publishDate 2022-10-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-cfa701f62a5d46c6ad64b004ce8f4dd32022-12-22T02:37:13ZengNature PortfolioScientific Reports2045-23222022-10-0112111510.1038/s41598-022-21526-4An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infectionsOhad Meir0Fadia Zaknoon1Amram Mor2Faculty of Biotechnology and Food Engineering, Technion – Israel Institute of TechnologyFaculty of Biotechnology and Food Engineering, Technion – Israel Institute of TechnologyFaculty of Biotechnology and Food Engineering, Technion – Israel Institute of TechnologyAbstract Scarcity of effective treatments against sepsis is daunting, especially under the contemporary standpoints on antibiotics resistance, entailing the development of alternative treatment strategies. Here, we describe the design and antibiotic adjuvant properties of a new lipopeptide-like pentamer, decanoyl-bis.diaminobutyrate-aminododecanoyl-diaminobutyrate-amide (C10BBc12B), whose sub-maximal tolerated doses combinations with inefficient antibiotics demonstrated systemic efficacies in murine models of peritonitis-sepsis and urinary-tract infections. Attempts to shed light into the mechanism of action using membrane-active fluorescent probes, suggest outer-membrane interactions to dominate the pentamer’s adjuvant properties, which were not associated with typical inner-membrane damages or with delayed bacterial growth. Yet, checkerboard titrations with low micromolar concentrations of C10BBc12B exhibited unprecedented capacities in potentiation of hydrophobic antibiotics towards Gram-negative ESKAPE pathogens, with an apparent low propensity for prompting resistance to the antibiotics. Assessment of the pentamer’s potentiating activities upon efflux inhibition incites submission of a hitherto unreported, probable action mechanism implicating the pentamer’s de-facto capacity to hijack bacterial efflux pumps for boosting its adjuvant activity through repetitive steps including outer-membrane adhesion, translocation and subsequent expulsion.https://doi.org/10.1038/s41598-022-21526-4
spellingShingle Ohad Meir
Fadia Zaknoon
Amram Mor
An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections
Scientific Reports
title An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections
title_full An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections
title_fullStr An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections
title_full_unstemmed An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections
title_short An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections
title_sort efflux susceptible antibiotic adjuvant with systemic efficacy against mouse infections
url https://doi.org/10.1038/s41598-022-21526-4
work_keys_str_mv AT ohadmeir aneffluxsusceptibleantibioticadjuvantwithsystemicefficacyagainstmouseinfections
AT fadiazaknoon aneffluxsusceptibleantibioticadjuvantwithsystemicefficacyagainstmouseinfections
AT amrammor aneffluxsusceptibleantibioticadjuvantwithsystemicefficacyagainstmouseinfections
AT ohadmeir effluxsusceptibleantibioticadjuvantwithsystemicefficacyagainstmouseinfections
AT fadiazaknoon effluxsusceptibleantibioticadjuvantwithsystemicefficacyagainstmouseinfections
AT amrammor effluxsusceptibleantibioticadjuvantwithsystemicefficacyagainstmouseinfections